骨髓衍生中细胞的捐赠者间和捐赠者内部变异性:对临床应用的含义
Alpa Trivedi1, Maximillian Lin1, Byron Miyazawa1
1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
Cytotherapy
|June 9, 2024
概括
介酶体 stromal 细胞 (MSCs) 显示出影响患者生物标志物的供体依赖性变异性. 这影响了急性呼吸困扰综合征 (ARDS) 治疗的治疗潜力.
科学领域:
- 细胞生物学 细胞生物学
- 再生医学是一种再生医学.
- 免疫学 免疫学 免疫学
背景情况:
- 介质细胞 stromal 细胞 (MSCs) 是有希望的治疗炎症和血管疾病.
- 骨髓衍生MSCs (BM-MSCs) 在2a期试验中被发现对中度至严重的急性呼吸困扰综合征 (ARDS) 安全.
- 这项研究分析了START试验中的MSC剂量,考虑了捐赠者和采集时间之间的差异.
研究的目的:
- 为了将MSC特性与与ARDS结果相关的患者血生物标志物相关联.
- 调查MSC特征的捐赠者间和捐赠者内部变异性.
- 评估MSCs对内皮屏障透性的功能影响.
主要方法:
- 对生命力,生长,新陈代谢和表面/蛋白质标记物进行评估的MSC供体批量.
- 评估免疫调节能力和内皮细胞透性调节.
- 与患者血生物标志物 (ANG-2,蛋白C) 输血后的相关的MSC特性.
主要成果:
- MSC标记体表达和内皮屏障保护在所有供体批量中都是一致的.
- 在其他体外试验中发现了显著的捐赠者间和捐赠者内部变异性.
- 患者的血ANG-2和蛋白C水平与MSC活力相关,以依赖于捐赠者的方式.
结论:
- 捐赠者依赖的 (相互) 和采集依赖的 (内部) 影响影响患者生物标志物的表达.
- 强调在治疗应用中考虑MSC供体变异性的重要性.
- 表明需要对ARDS治疗进行标准化MSC表征.
相关概念视频
Bone Marrow Sampling and Transplants
324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K


